Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Arafura Rare Earths Ltd

ARU

Arafura Rare Earths Ltd. engages in the exploration and development of mineral resource properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-11-05. The firm produces rare earth products from the Nolans Project. The Nolans Project consists of a mine, process plant, including beneficiation, extraction and separation plants, and related infrastructure to be constructed and located at the Nolans site, approximately 135 kilometers north of Alice Springs in Australia's Northern Territory. Its rare earth products are Neodymium-Praseodymium (NdPr) oxide, and Mixed middle-heavy rare earths (SEG/HRE) oxide. NdPr oxide is the Company's flagship product, which is used by magnet and magnet alloy customers. The Company’s primary products from the Nolans project are rare earths, which are used in catalytic converters in automobiles, consumer electronics, energy efficiency lighting, optics, alloys, advanced ceramics and permanent magnets that enable e-mobility and renewable energy applications.

Renascor Resources Limited

RNU

Renascor Resources Ltd. engages in the exploration and evaluation of mineral property. The company is headquartered in Adelaide, South Australia. The company went IPO on 2010-12-15. The firm's projects include Siviour, Carnding, Marree, and Olary. The Carnding Project contains several near-surface, high-grade gold prospects (up to 16 g/t from previous drilling) in South Australia's Central Gawler Craton. At Carnding, the Company is targeting shallow, high-grade gold occurrences. Within the project area, the Company has identified multiple high priority gold targets based on shallow drilling. The Marree Project is a copper-prospective ground position within South Australia's Adelaide Fold Belt. Its exploration program is focused on identifying and drilling prospects for large tonnage Zambian Copper Belt-style, sedimentary copper deposits. The company holds 100% interest in the remaining Marree Project exploration licenses, EL 6170 and EL 6403.

Sayona Mining Limited

SYA

Sayona Mining Ltd. engages in sourcing and developing raw materials required for constructing lithium-ion batteries. The company is headquartered in Brisbane, Queensland. The company went IPO on 2004-03-30. The firm's projects include Authier Lithium Project, Tansim Lithium Project, Moblan Lithium Project, Lac Albert Lithium Project, Western Australia Lithium Projects, Western Australia Gold Projects, and Western Australia Graphite Projects. The Authier Lithium project is situated approximately 45 kilometers (km) northwest of the city of Val d'Or, a mining service center in Quebec. The project area comprises 19 mineral claims totaling 653 hectares and extends approximately 3.4 km in the east-west, and 3.1 km in a north-south direction, respectively. The Tansim Lithium project is situated approximately 82 km southwest of the Authier Lithium Project. The project comprises 355 mineral claims spanning 20,546 hectares (ha) and is prospective for lithium, tantalum, and beryllium. The Moblan Lithium project is located in the Eeyou-Istchee James Bay region of northern Quebec.

Clarity Pharmaceuticals Ltd

CU6

Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. The company is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. The company has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.